The cost-effectiveness of transcatheter aortic valve replacement in high-risk patients with severe aortic stenosis is access-site dependent, according to an analysis of the PARTNER trial published in the Journal of the American College of Cardiology. The findings support the transfemoral route, which demonstrated similar overall costs to surgery but shorter stays in the ICU and hospital overall and shorter procedural time.

Full Story:

Related Summaries